Although a conditionally replicating adenovirus (CRA) exhibiting cancer-selective replication and induction of cell death is an innovative potential anticancer agent, current imperfections in cancer specificity and efficient viral replication limit the usefulness of this technique. Here, we constructed survivin-responsive CRAs (Surv.CRAs), in which expression of the wild-type or mutant adenoviral early region 1A (E1A) gene is regulated by the promoter of survivin, a new member of the inhibitor of apoptosis gene family. We explored the cancer specificity and effectiveness of viral replication of Surv.CRAs, evaluating their potential as a treatment for cancer. The survivin promoter was strongly activated in all cancers examined at levels similar to or even higher than those seen for representative strong promoters; in contrast, low activity was observed in normal cells. Surv.CRAs efficiently replicated and potently induced cell death in most types of cancer. In contrast, minimal viral replication in normal cells did not induce any detectable cytotoxicity. A single injection of Surv.CRAs into a preestablished tumor expressing survivin, even at relatively low levels, induced significant tumor death and inhibition of tumor growth. Furthermore, Surv.CRAs were superior to telomerasedependent CRAs, one of the most effective CRAs that have been examined to date, both in terms of cancer specificity and efficiency. Thus, Surv.CRAs are an attractive potential anticancer agent that could effectively and specifically treat a variety of cancers. (Cancer Res 2005; 65(12): 5284-91) 
Survivin-Responsive Conditionally Replicating Adenovirus Exhibits Cancer-Specific and Efficient Viral Replication Introduction
Conditionally replicating adenoviruses (CRAs), which selectively replicate in and kill tumor cells, may be an attractive tool for innovative cancer therapy (1) . Achievement of both cancer specificity and efficient viral replication is critical for any CRAoriented strategy. The CRAs that have been reported to date can primarily be classified into one of two groups (1) . The first category employs the strategy of attenuating viral replication in normal cells by mutating cell cycle-inducing adenoviral genes necessary for viral replication; representatives of this group are the mutant type (MT) adenoviruses lacking an RB-binding site within early region 1A (E1A) and the MT adenoviruses lacking a p53-binding protein encoded by the early region 1B (E1B)-55K gene (2) (3) (4) . Although these CRAs exhibit potential in cancer cells, these viruses do replicate and cause some cytopathic effects in normal cells (4) (5) (6) . The second group of CRAs alters the regulation of E1A expression. E1A is the first gene to be transcribed after infection with wild-type (WT) adenoviruses, transactivating the viral and cellular genes critical for producing infective adenoviruses. CRAs of this category reproduce in a tumor-specific manner by replacing the native E1A promoter with a tissue-and tumor-specific promoter, such as the prostate-specific antigen promoter (7), the a-fetoprotein promoter (8) , the midkine promoter (9) , or the tyrosinase promoter (10) . Although previous studies of this CRA strategy have been promising, the use of tissue-specific promoters has the disadvantage of targeting only limited types of cancer. In addition, these promoters show insufficient cancer specificity (leaky transactivation in normal cells) and weak activity even in cancer cells. Thus, viral targeting and replication for previously reported CRAs may not have achieved sufficient efficiency or cancer specificity. The use of a novel and ideal promoter able to induce strong expression in a cancer-specific manner is crucial to circumventing these problems.
Survivin, a new member of the inhibitor of apoptosis gene family, was reported to be expressed in high levels in cancerous but not normal tissues (11) . Clinical studies have indicated a positive correlation between high survivin expression levels and a poor prognosis, an accelerated rate of recurrence, and an increased resistance to therapy in cancer patients (12) . Survivin is predominantly expressed during the G 2 -M phase of the cell cycle, functioning in mitosis via interactions with microtubules (13) . In addition, the survivin promoter successfully regulates transgene expression in a cancer-specific manner (14) . Moreover, studies have suggested that a putative region of the survivin promoter is likely responsible for the induction of cancer-specific expression in tumors at high levels (15, 16) . The promoter contains multiple cell cycle-dependent elements and a cell cycle gene homology region, which may control expression of various G 2 -M-regulated genes, including the survivin gene, in a manner correlating with G 2 -M cell cycle periodicity (13, (15) (16) (17) .
In this study, we generated and analyzed two survivin-responsive CRAs (Surv.CRAs). Surv.CRAwt and Surv.CRAmt expressed WT and MT E1A under the control of the survivin promoter, respectively. We finally compared these Surv.CRAs to a recently reported CRA, in which E1A is regulated by the telomerase reverse transcriptase (TERT) promoter (Tert.CRA), currently one of the best CRAs available (18) (19) (20) .
Materials and Methods
Cell lines. The human cell lines MKN-1 and MKN-45 (gastric cancer cell lines); HCT-15, LoVo, and Colo-205 (colon cancer cell lines); HepG2 and Hep3B (hepatoma cell lines); HeLa (a cervical cancer cell line); SaOS-2, HOS-MNNG, and KHOS-NP (osteosarocoma cell lines); and WI-38 (a primary lung fibroblast) were maintained in DMEM supplemented with penicillin/streptomycin and 10% fetal bovine serum. Primary human osteoblasts, obtained from Bio Whittaker (Walkersville, MD), were maintained according to the manufacturer's protocol.
Generation of adenoviruses. A region of the mouse survivin gene promoter (À173 to À19), which contains two cell cycle-dependent elements and one cell cycle gene homology region, was obtained from mouse genomic DNA by PCR using the following primers: sense (S)-Surv.pr 5V -AGATGGGCGTGGGGCGGGAC-3V and antisense (AS)-Surv.pr 5V -TCCGCCAAGACGACTCAAAC-3V. Generation of Surv.CRAwt, Surv.CRAmt, and Tert.CRAwt viruses, which contained WT or MT E1A downstream of either the survivin or TERT promoter (À181 to +79; kindly provided by Dr. S. Kyo, Kanazawa University School of Medicine; ref. 21) , E1BD55K downstream of the cytomegalovirus immediate-early gene enhancer/ promoter (CMV promoter), and the enhanced green fluorescent protein (EGFP) gene downstream of the CMV promoter, was done using a novel method developed by our group (22) .
An E1-deleted replication-defective adenovirus expressing EGFP (Ad.DE1) and E1-deleted adenoviruses expressing the LacZ gene under the control of the Rous sarcoma virus long-terminal repeat (RSV promoter), the CMV promoter, the survivin promoter, or the TERT promoter (Ad.RSVLacZ, Ad.CMV-LacZ, Ad.Surv-LacZ, and Ad.Tert-LacZ, respectively) were generated and prepared as described previously (23) .
Reverse transcription-PCR analysis. Extraction of total RNA from the cells and the semiquantitative reverse transcription-PCR (RT-PCR) analyses were done as described previously (24) , with the following primer sets and annealing temperatures: S-Surv 5V -CCCTTGGTGAATTTTTGAAA-3V and AS-Surv 5V -TGGTGCCACTTTCAAGACAA-3V for human survivin at 56jC; S-TERT 5V-TTCCTGCACTGGCTGATGAGTGT-3V and AS-TERT 5V-CGC-TCGGCCCTCTTTTCTCTG-3V for human TERT at 59jC (25) ; and S-HPRT 5V -CCTGCTGGATTACATTAAAGCACTG-3V and AS-HPRT 5V -AAGGGCATA-TCCAACAACAA-3V for hypoxanthine guanine phosphoribosyl transferase (HPRT) as an internal control at 57jC (24, 26) .
Promoter activities and adenoviral gene transduction efficiency. Cells (5 Â 10 5 cells per plate) were infected with Ad.CMV-LacZ, Ad.RSVLacZ, Ad.Surv-LacZ, or Ad.Tert-LacZ at a multiplicity of infection (MOI) of 30 for 24 hours. After harvesting, cellular h-galactosidase (h-gal) activity was measured as previously described (27) .
The adenoviral gene transduction efficiency (AGTE) for each cell in vitro was determined 48 hours after infection with Ad.CMV-LacZ at an MOI of 30, as previously described (27) (28) (29) .
Flow cytometric analysis. After infection with each adenovirus, cells were detached with trypsin and fixed in 4% paraformaldehyde. The percentage of EGFP-positive cells was then analyzed by flow cytometry on a FACSCalibur using CELLQuest software (Becton Dickinson, San Jose, CA).
Cytotoxic effects in vitro. After plating in 96-well plates, cells were infected with each adenovirus at a variety of MOIs. Cell viability was determined 3 and 5 days after adenoviral infection using a WST-8 assay (Dojindo Laboratories, Mashiki, Japan) according to the manufacturer's protocol.
Therapeutic effects in vivo in animal experiments. HOS-MNNG cells (5 Â 10 6 cells) were injected s.c. into the back of 5-week-old male BALB/c athymic nude mice. After the s.c. tumors reached 6 to 10 mm in diameter, the mice were randomly divided into three groups. Each group was given a single injection of 1 Â 10 8 plaque-forming unit (pfu) Surv.CRAwt (n = 9), Surv.CRAmt (n = 8), or Ad.DE1 (n = 8) in 50 AL of 10 mmol/L Tris-HCl (pH 7.4)/1 mmol/L MgCl 2 /10% (v/v) glycerol/hexadimethrine bromide (20 Ag/mL) into the s.c. tumor. In another comparative experiment, tumorbearing mice were infected with Tert.CRAwt (n = 9), Surv.CRAwt (n = 8), or Ad.DE1 (n = 11) as described above. Tumor size was then monitored twice a week using digital calipers. Tumor volume was calculated according to the following formula: volume = long axis Â (short axis) 2 Â 0.5 (29, 30) . For histopathologic analysis, the tumors were fixed in 10% buffered formalin, embedded in paraffin, cut into 4-Am serial sections, and stained with H&E.
The protocol for this animal experiment was approved by the Animal Research Committee of Kurume University. All animal experiments were done in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals.
Statistical analysis. Data are represented as the means F SE. Statistical significance was determined using the Student's t test. P < 0.05 were considered to indicate statistical significance.
Results
Survivin mRNA was expressed in various cancer cell lines. The RT-PCR analyses showed that survivin mRNA was expressed in multiple cancer cells derived from a variety of tissue origins; Fig. 1 . B, a high-power phase-contrast microscopic image taken 7 days after infection with control Ad.DE1 or Surv.CRAwt showed that all of the LoVo and HepG2 cells underwent cytopathic effect after infection with Surv.CRAwt only. In contrast, no cytopathic effect was observed in WI-38 cells after infection with either adenovirus.
this finding was consistent with previous reports (ref. 11; Fig.  1A ). The levels of survivin mRNA, however, varied widely among the different cancer cell lines. Survivin mRNA expression was remarkably high in both hepatoma cell lines tested, HepG2 and Hep3B, and in one of the osteosarcoma cell lines, SaOS-2. The levels in the other cell lines were only moderate or relatively low. Survivin mRNA was also detected in normal WI-38 human fibroblasts and primary human osteoblasts; these levels, however, were relatively low in comparison to those seen in the cancer cell lines.
Strong cancer-specific activity of the survivin promoter. The survivin promoter provided strong transcriptional activation in all of the cancer cell lines that showed sufficient viral transduction (Fig. 1B) . The low levels or absence of h-gal activity after infection with adenoviruses in either Colo-205 or KHOS-NP cells was apparently due to very low levels of AGTE in these cells and not to a low activity of the survivin promoter. h-gal activity was not detected in this group even after infection with Ad.RSV-LacZ or Ad.CMV-LacZ at the same MOI (MOI of 30). The apparent variability in h-gal levels was also due to both the variability of AGTE levels in individual cells and the cellular activity required to express the transgenes and not the variability in survivin promoter activity. In seven of the remaining nine cancer cell lines, the survivin promoter exhibited stronger activity than either the RSV promoter or the CMV promoter, two representative ubiquitously strong promoters (27, 28) . Notably, the survivin promoter was stronger than both the RSV and CMV promoters in HepG2 cells. In two additional cell lines, HCT-15 and LoVo, the survivin promoter displayed activity levels very similar to those observed for the RSV and CMV promoters. In contrast, survivin promoter activity was not detected in normal WI-38 fibroblasts despite both high levels of RSV and CMV promoter activity and moderate to high AGTE levels. Despite detectable, albeit low, levels of endogenous survivin expression, no detectable transactivation could be observed in normal cells with the use of this survivin promoter (Fig. 1B) . Thus, the survivin promoter region and length of the transcriptional regulatory element used in these experiments are suitable to induce strong transactivation in all cancer types examined here in a tumor-specific manner.
Surv.CRAs efficiently and selectively replicated in cancer. After infection with Surv.CRAwt or Surv.CRAmt, the number of EGFP-positive cells increased in a time-dependent manner in all of the cancer cell lines analyzed, indicating the efficient replication of both Surv.CRAs (Fig. 2) . Cytopathic effect was efficiently induced within a short period of time after the appearance of EGFP positivity. The speed of the Surv.CRA spreading was consistent with the observed levels of h-gal activity (Fig. 1B) , except for MKN-45 cells. In these cells, the Surv.CRAs replicated very rapidly, spreading throughout the entire culture dish at a rate similar to that seen in LoVo, HepG2, and Hep3B cells. The slow yet still apparent spread of the Surv.CRAs was even observed in Colo-205 cells, despite a low AGTE in the initial infection. This phenomenon likely results from high levels of endogenous survivin expressed, suggesting that efficient viral replication within cells may overcome the disadvantage of low AGTE. In contrast, the percentage of EGFP-positive cells did not clearly increase over a 7-day period in normal WI-38 cells, although the EGFP fluorescence intensity within each cell increased minimally. In addition, no cytopathic effect was observed in WI-38 cells even at 7 days after infection with Surv.CRAs.
To verify tumor-specific replication of both Surv.CRAs accurately and quantitatively, we did flow cytometric analysis using two representative cancer cell lines, HepG2 and HOS-MNNG, as well as normal WI-38 cells. HepG2 cells exhibited the highest levels of survivin expression, the highest AGTE levels, and the strongest survivin promoter activity, resulting in rapid amplification of the Surv.CRAs (Fig. 2) . HOS-MNNG showed low to moderate levels of these properties, resulting in lower but significant viral replication. Twenty-four hours after infection with either of the adenoviruses at the MOI that initially provided approximately 20% AGTE, Surv.CRAs propagated rapidly, spreading to >90% of HepG2 and HOS-MNNG cells. Under these conditions, we could not observe any significant amplification or spread of the control replicationdefective Ad.DE1 (Fig. 3) . In contrast, the propagation and resulting spread of Surv.CRAs remained minimal in WI-38 cultures. Thus, both Surv.CRAs replicated more efficiently in cancer cells, even those expressing survivin at relatively low levels, with moderate AGTE levels, than in normal WI-38 cells. In addition, we did not detect any significant differences in the phenotypic characteristics of Surv. CRAwt and Surv.CRAmt in any of the cell types tested.
Surv.CRAs specifically kill cancer cells in vitro. To assess the selective killing of cancer cells by Surv.CRAs, we conducted a cell viability assay (Fig. 4) . In two representative cell lines showing both high AGTE and high levels of survivin expression, HepG2 and Hep3B cells, Surv.CRAs induced prominent cytotoxic effects as early as 3 days, even when infection was done at a low MOI (0.1). Both hepatoma cell lines were sensitive to adenoviral cytotoxicity; cytotoxic effects were minimally but clearly seen 5 days after infection at an MOI of 0.1 with the control, E1-deleted Ad.DE1. In HOS-MNNG cells, which exhibited low expression of survivin and moderate AGTE levels, both Surv.CRAs induced more prominent cytotoxicity than Ad.DE1. The cytotoxic effects were amplified in a dose-dependent manner when initial infection at increasingly higher MOI (Fig. 4) . In contrast to these results in cancer cell lines, neither Surv.CRA induced cytotoxic effects in normal WI-38 fibroblast cells, even 5 days after infection at an MOI of 1. Thus, both Surv.CRAs efficiently induced cell death in three cancer cell lines in contrast to the lack of clear toxicity observed in normal WI-38 cells. In addition, we did not observe any significant differences in the cytotoxicity of Surv.CRAwt and Surv.CRAmt between the cell types tested, including the normal WI-38 cells, RB-intact HepG2 cells, and RB-deficient Hep3B cells.
Surv.CRA inhibited tumor growth in vivo. Using an animal model of preestablished s.c. tumors, we examined the therapeutic potential of both Surv.CRAs in vivo. We intentionally used an HOS-MNNG osteosarcoma cell line that expressed relatively low levels of survivin and showed moderate levels of AGTE to assess the therapeutic potentials of these vectors in a wider range of cancers. A single intratumoral administration (1 Â 10 8 pfu) of Surv.CRAwt or Surv.CRAmt significantly inhibited tumor growth in comparison to the same dose of Ad.DE1 (Fig. 5A) . Statistically significant differences in the tumor size were seen between Surv.CRAs-treated and Ad.DE1-treated mice as early as 11 days after administration and continuing thereafter. As assessed by macroscopic and microscopic examination, the therapeutic effects of both Surv. CRAs were more significant; the tumor nodules in Surv.CRAtreated mice contained large necrotic areas, whereas the nodules in Ad.DE1-treated mice consisted primarily of viable tumor cells histologically showing active malignant features ( Fig. 5B and C) . These results suggest the therapeutic potential and general utility of Surv.CRAs for the treatment of cancer.
The superiority of Surv.CRAs to a Tert.CRA. We compared the viral properties of Surv.CRAs with those of Tert.CRA. The expression levels of endogenous TERT varied among cancer cell lines; HOS-MNNG cells, as well as HepG2 cells, expressed TERT mRNA at very high levels (Fig. 6A) , in contrast to the relatively low level of survivin expression in HOS-MNNG cells (Fig. 1A) . Nevertheless, the activity of the survivin promoter in HOS-MNNG cells was higher than that of the TERT promoter, as well as in HepG2 cells (Fig. 6B) . These results suggest that the survivin promoter may be more active than the TERT promoter among multiple cancer cell types.
To precisely analyze the differences in the efficiency and attenuation of viral replication between Surv.CRAs and Tert.CRA in cancerous and normal cells, we did flow cytometric analysis after infection of three types of cells at low MOI (Fig. 6C) . Surv.CRAwt exhibits more efficient replication in both HepG2 and HOS-MNNG cells than that seen in Tert.CRAwt cells, although the former virus is more quiescent in normal WI-38 cells than the latter.
We compared the therapeutic potentials of Surv.CRAwt and Tert.CRAwt in tumor-bearing animals (Fig. 6D) . Although we did not find a statistically significant difference in the effects of Surv.CRAwt and Tert.CRAwt, both viruses significantly decreased tumor size in animals from the tumor volumes observed in mice treated with the control Ad.DE1 virus. Tumor volumes in Surv.CRAwt-treated mice were smaller than those in Tert.CRAwttreated animals; in addition, the difference between the Surv. CRAwt and control Ad.DE1 groups was more significant (smaller P) than the difference between the Tert.CRAwt and Ad.DE1 groups.
Discussion
This study provides the first report of two survivin-responsive CRAs, both showing efficient cancer-specific replication and potent therapeutic effects against cancers both in vitro and in vivo.
One of the attractive features of Surv.CRAs is their ability to target a variety of cancers. Surv.CRAs showed efficient propagation and induced cell death in a wide variety of tumor cells with a variety of phenotypes, including low levels of survivin expression. The problem of low AGTE in certain cancer types is a critical issue in adenoviral gene therapy; Surv.CRAs are no exception. Further attempts should be made to improve adenoviral infectivity. Nevertheless, this study showed that Surv.CRAs propagated even in cell types with low AGTE values, a promising result for the potential of these vectors as therapeutic agents. In addition, we intentionally used HOS-MNNG cells, which express survivin at relatively low levels and exhibit only moderate AGTE, for in vivo animal studies. The anticancer effect of Surv.CRAs under these conditions suggests that this agent may elicit therapeutic effects in many cancer types. Moreover, recent studies have detailed promising approaches to overcome the obstacle of low AGTE, such as fiber modification (31) (32) (33) ; these techniques could be also be directly and feasibly applied to Surv.CRAs (22) . Fibermodified Surv.CRA may enhance the cancer specificity and efficacy of this therapy for a broader range of cancer types and should be explored further.
Another crucial requirement for optimal CRA is attenuation of viral replication in normal cells. Currently, one of the best available CRAs may be Tert.CRA; TERT, the major determinant of telomerase activity, is expressed at high levels in many cancer cells but not in normal cells (34) . Several recent studies have shown cancerselective replication and anticancer effects of Tert.CRAs (18) (19) (20) . After examining the endogenous expression levels and promoter activity of TERT in a variety of cancer and normal cells, we compared the viral replication of Surv.CRAwt to that of Tert.CRAwt in both cancer and normal cells. Surv.CRAwt showed greater promise; the replication of Surv.CRAs in normal cells was more attenuated than that of the Tert.CRA, whereas Surv.CRAwt was more efficient in replicating in two independent cancer cell types, including HOS-MNNG. As HOS-MNNG expressed survivin and TERT at low and high levels, respectively, it is likely that Surv.CRAs are superior to Tert.CRAs in both cancer specificity and efficiency, although the general applicability of this trend will need to be confirmed in future studies.
Previous studies have not yet explored whether deletion of the RB-binding domain when combined with the modulation of E1A expression using a tumor-specific promoter provides additional advantages or disadvantages over either approach alone (4) . In this study, Surv.CRAmt did not provide an enhanced cancer specificity or an attenuation of viral replication in normal cells but also do not reduce viral replication in the cancer cells examined, including both RB-deficient and RB-intact tumor cells and normal fibroblast cells. The survivin promoter may confer such a high level of cancer specificity that these additional viral modifications do not provide a clear additional advantage. It is also possible that both RB-dependent and survivin-dependent cancer specificities target cell cycle dysregulation; therefore, the cancer specificity of RB-and survivin-dependent viruses may overlap to some extent. Future studies should be conducted to modify further the expression elements of other adenoviral genes using different promoters that target cancer-specific genetic events independent of cell cycle dysregulation, because the replication of Surv.CRAs in normal cells was greatly attenuated but not completely abrogated.
In conclusion, this study showed the therapeutic potential of survivin-responsive CRAs; these Surv.CRAs confer cancer-specific replication and cytotoxicity and thus may provide an attractive therapeutic agent for the treatment of cancer.
